About Immune Targeting Systems
Immune Targeting Systems is a company based in London (United Kingdom) founded in 2003 was acquired by Altimmune in February 2015.. Immune Targeting Systems has raised $20.3 million across 2 funding rounds from investors including Altimmune, Truffle Capital and London Technology Fund. The company has 46 employees as of December 31, 2021. Immune Targeting Systems operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
- Headquarter London, United Kingdom
- Employees 46 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Altimmune Uk Limited
- Date of Incorporation 05 Oct, 1992
- Jurisdiction LEEDS, ENGLAND
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Immune Targeting Systems
Immune Targeting Systems has successfully raised a total of $20.3M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $13.2 million completed in March 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $13.2M
-
First Round
First Round
(16 Jul 2007)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2010 | Amount | Series A - Immune Targeting Systems | Valuation |
investors |
|
| Jul, 2007 | Amount | Series A - Immune Targeting Systems | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Immune Targeting Systems
Immune Targeting Systems has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Altimmune, Truffle Capital and London Technology Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Truffle Capital is recognized as a leading European venture capital firm.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Investments are made in innovative life science companies globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Immune Targeting Systems
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Immune Targeting Systems
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Immune Targeting Systems Comparisons
Competitors of Immune Targeting Systems
Immune Targeting Systems operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Developer of biologics to treat hepatitis B infection
|
|
| domain | founded_year | HQ Location |
Developer of computationally designed VLP vaccines for treating multiple infections
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Immune Targeting Systems
When was Immune Targeting Systems founded?
Immune Targeting Systems was founded in 2003 and raised its 1st funding round 4 years after it was founded.
Where is Immune Targeting Systems located?
Immune Targeting Systems is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Is Immune Targeting Systems a funded company?
Immune Targeting Systems is a funded company, having raised a total of $20.3M across 2 funding rounds to date. The company's 1st funding round was a Series A of $7.1M, raised on Jul 16, 2007.
How many employees does Immune Targeting Systems have?
As of Dec 31, 2021, the latest employee count at Immune Targeting Systems is 46.
What does Immune Targeting Systems do?
Immune Targeting Systems was founded in 2003 in London, United Kingdom, within the biotechnology sector. Prophylactic and therapeutic vaccines targeting mutating viruses are developed using a fluorocarbon-conjugated synthetic peptide platform. Broad HLA and antigen coverage, along with product stability, are achieved in these T-cell vaccines. Protection against infectious diseases is provided, including Flunisyn as a depot vaccine for influenza. The company was acquired by Vaxin in February 2015.
Who are the top competitors of Immune Targeting Systems?
Immune Targeting Systems's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Who are Immune Targeting Systems's investors?
Immune Targeting Systems has 5 investors. Key investors include Altimmune, Truffle Capital, London Technology Fund, Novartis Venture Fund, and Healthcap.